Errata - English

Line 7 of Analysis: Change
R_U = peak area ratio of ibuprofen to valerophenone from the Sample solution
R_S = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
R_U = peak area ratio of ibuprofen related compound C to valerophenone from the Sample solution
R_S = peak area ratio of ibuprofen related compound C to valerophenone from the Standard solution

Line 6 of 6.50.20. Solutions: Change
An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.
to:
An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with, or 1 part by weight of a solid shall be dissolved in, a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.

Line 1 of Standard preparation: Change
Prepare as directed in the chapter.
to:
Transfer 5.0 mL (5 μg of arsenic) of the Standard Arsenic Solution to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume.
AND
Delete:
Control preparation: Transfer 5.0 mL (5 μg of As) of the Standard preparation to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume.
AND
Line 1 of Acceptance criteria: Change
the absorbance due to any red color from the Test preparation does not exceed that produced by the Control preparation.
to:
the absorbance due to any red color from the Test preparation does not exceed that produced by the Standard preparation.

Line 14 of Analysis: Change
Result = [(V × N × F)/W] × 100
to:
Result = [(V × M × F)/W] × 100
AND
Line 15 of Analysis: Change
V = volume of titrant consumed by the Sample (mL)
N = actual normality of the titrant (mEq/mL)
F = equivalency factor, 136.14 mg/mEq
to:
V = volume of Titrant consumed by the Sample (mL)
M = actual molarity of the Titrant (mM/mL)
F = equivalency factor, 136.14 mg/mM

Line 14 of Analysis in Content of Total Phenols: Change
C_S = concentration of the relevant analyte in the corresponding Standard solution
C_U = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
C_S = concentration of the relevant analyte in the corresponding Standard solution (mg/mL)
C_U = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)
AND
Line 20 of Analysis in Content of Dodecatetraenoic Acid Isobutylamides: Change
C_U = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
C_U = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)

Line 5 of Magnesium stock solution: Change
Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg)
to:
Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of magnesium (Mg)

Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1500:500:2:2:0.4). Make adjustments if necessary (see System Suitability under Chromatography <621>).
to:
Transfer 2 grams of ammonium acetate, 2 mL of glacial acetic acid, and 0.4 mL of triethylamine to a suitable flask containing 1500 mL of water and 500 mL of acetonitrile. Stir until all solids are dissolved and well mixed, then filter and degas.

Line 5 of Analysis in Limit of Gallic Acid: Change
Separately calculate the percentages of gallic acid
to:
Calculate the percentage of gallic acid
AND
Line 5 of Analysis in Limit of Caffeine: Change
Separately calculate the percentages of caffeine
to:
Calculate the percentage of caffeine

Line 7 of Procedure: Change
(293.36/329.82)10,000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)
to:
(293.36 / 329.83)10,000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)
AND
Line 8 of Procedure: Change
329.82
to:
329.83

Footnote a of Table 1: Change
(S)-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
AND
Footnote b of Table 1: Change
(S)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.

Line 6 of Analysis: Change
Result = (A_U/A_S) × (C_S/C_U) × P × 100
to:
Result = (A_U/A_S) × (C_S/C_U) × P × F × 100
AND
After P in definition list: Add
F = conversion factor, 0.001 mg/μg

Line 2 of USP Valsartan Related Compound A RS: Change
(R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine.
AND
Line 2 of USP Valsartan Related Compound B RS: Change
(S)-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
AND
Line 2 of USP Valsartan Related Compound C RS: Change
(S)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.

Line 1 of Sample solution: Change
Equivalent to 600 mg/mL of anhydrous sodium acetate
to:
Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water.
AND
Line 1 of Analysis: Change
To 5 mL of Sample solution add
to:
To the Sample solution add